Manufacturing & Packaging

The pre-approval pertains to a solid oral dose product that the CDMO will manufacture for a global pharmaceutical company.

The San Antonio facility will be taking this biomanufacturing initiative by the end of Q3 2024.

The deal exponentially grows the CDMO’s biopharma capabilities.

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

Analyzing the divergent paths undertaken by small biotech and large pharma companies in drug development.

The financial commitment includes a pair of expansion plans occurring in the United States and Europe.

The 50,000 square-foot facility has the ability to handle various batch sizes and dosage forms.

The construction of 100,000 square-foot facility will boost the site's filling capacity to 140 million units per year.

New production line represents Rentschler Biopharma SE’s biggest investment in its 150-year history.

The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.

The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.

The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.

The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.

The agreement will look to further develop cell and gene therapies for the treatment of hematological cancers.

The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.

The partnership will offer an end-to-end manufacturing solution for biopharma companies.

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.

The $530 million investment will accelerate the company’s development and production process for therapies in the rare disease space.

New innovations that are contributing to industry environmental efforts.

The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.

The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies.

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.